11th Biennial Ovarian Cancer Research Symposium
Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin
Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Glioblastoma
Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma
Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: impact of p53 and platinum-resistance
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma
The unique mechanism of action of dianhydrogalactitol (VAL-083) may provide a new treatment option for chemo-resistant cancers
Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the Treatment of Pediatric Brain
Exploring the Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment
Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer